Market Trends of Europe Insulin Infusion Pumps Industry
Insulin Pump Monitors Hold Largest Market Share
Countries in Europe are facing a high burden of diabetes expenditures. According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion, and it is expected to increase to USD 174 billion by 2040. According to the same source, 21,600 children are added to the type-1 diabetic population every year.
These figures indicate that approximately 9% of the total healthcare expenditure in Europe is spent on diabetes. For patients relying on insulin pumps or multiple daily injections (MDI), CGM systems are an effective tool. They help in the improvement of glycemic balance without aggravating the danger of severe hypoglycemia.
In Europe, a variety of insulin pumps are available. Conventional insulin pumps have an insulin reservoir (or container) and a pumping mechanism attached to the body with tubing and an infusion set. Other insulin patch pumps are worn directly on the body and have a reservoir, pumping mechanism, and infusion set inside a small case. A separate device that allows for the programming of insulin delivery from the patch controls patch pumps wirelessly. Most insurance companies in Europe cover insulin pump therapy with variable out-of-pocket expenses.
The technology associated with insulin pumps combines glucose monitoring using CGM with advanced algorithms to predict low glucose and suspend insulin delivery. The technological innovation in the insulin pump market is likely to drive the market during the forecast period.
Germany Holds the Highest Market Share
The German Center for Diabetes Research (DZD) conducts extensive scientific research to develop effective prevention and treatment measures to prevent the emergence or progression of diabetes. Around 11% of the people living in Germany have private health insurance. Only people who fulfill certain criteria can have private health insurance. For example, the gross income of the person seeking insurance must have been above a certain threshold for at least one year. The developments in the insulin infusion pump reimbursement field are expected to bolster the adoption of insulin infusion pumps in Germany.
At least 7.2 percent of the population in Germany currently has diabetes, the majority of which is type-2 diabetes, depending on the estimate. Over the next 20 years, there can be a huge rise in the number of diabetics. Up to 12 million individuals in Germany could have type-2 diabetes in 20 years, according to researchers from the Robert Koch Institute (RKI) in Berlin and the German Diabetes Center (DDZ) in Düsseldorf. From 2015 to 2040, this is expected to represent an increase of up to 77%.
The DDZ scientists and their colleagues from the RKI published for the first time comprehensive projections of the future number of type-2 diabetes cases in Germany for all age groups based on the data of approximately 65 million subscribers to the German statutory health insurance and the Federal Statistical Office. They factored in current developments regarding newly diagnosed cases, rising life expectancy, and declining mortality rates as a result of medical advancements while calculating the development of case numbers between 2015 and 2040.
